NuVasive price target raised to $43 from $35 at Piper Jaffray Piper Jaffray raised its price target on NuVasive to $43 after the company's pre-announcement of better-than-expected Q4 revenue and its above consensus FY14 sales guidance. Piper says the stock is well-positioned to outperform again in 2014 and keeps an Overweight rating on the name.
NuVasive CEO news an incremental positive, says Piper Jaffray Piper Jaffray views NuVasive's naming Greg Lucier as its permanent CEO as an incremental positive despite the executive's lack direct experience in the spine industry. Piper notes its channel checks indicate no meaningful sales force disruption from the CEO transition. It reiterates an Overweight rating on NuVasive with a $56 price target.